SecBot SecBot

ORKA

Oruka Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000907654 Biotech & Drug Discovery
$105.35 +0.36 (+0.34%)
Nov 13 4:00 PM ET · prev $104.99
Market cap
$7.1B
Mid cap
Consensus
Buy
95% Buy or better · 20 analysts
Median target
$155.50
+48% · range $117.00–200.00
Next earnings
Nov 18
in 2 days
1 year
+273.2%
from $28.23 · Nov 17
30 days
+41.4%
from $74.48
52-week range
$26.40–113.08
−7% from high · low Jan 8
Avg volume 20D
997.8K
Nov 10 spike 2.61M
Short interest
6.46M
≈9.8% of shares · +5.8%
Days to cover
7.1
at average volume
Insider net
−$8.7M
since Oct 1 · excl. 6 subscriber-only trades
New fund stakes
0
Q3 2026 13F · 1 exit
SecBot read MIXED 17 reports · 90 days
Balance 3 bearish · 1 bullish · 13 neutral oldest → newest, height = score
Avg score ·High conf. 8/17 ·Next Earnings date, Nov 18, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    5 insiders sold $8.7M. Excludes 6 subscriber-only trades.

  • InstitutionsBULLISH

    Q3 2026: 31 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    19 of 20 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +5.8% to 6.46M shares. 7.1 days to cover, ≈9.8% of shares.

  • TrendUPTREND

    17% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
1
exit
FundMoveSharesValue
FRANKLIN TEMPLETON INCADD2,033,669$206.2M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED1,592,427$132.6M
WESTFIELD CAPITAL MANAGEMENT CO LPADD829,749$69.1M
BNP PARIBAS FINANCIAL MARKETSTRIM459,528$38.3M
Pictet Asset Management Holding SATRIM401,928$33.5M
UBS Group AGTRIM320,044$26.7M
Aberdeen Group plcTRIM210,659$23.1M
Fisher Asset Management, LLCDOUBLED215,593$18.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 95% rate it Buy or better
Strong Buy9Buy10Hold1Sell0Strong Sell0
12-month targets · 12 analysts

Price is below the lowest target. Median implies +48%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026BTIG
REITERATE
REITERATEBuy
Oct 27, 2026Guggenheim
REITERATE
REITERATEBuy
Oct 27, 2026Wedbush
REITERATE
REITERATEOutperform
Oct 19, 2026BTIG
REITERATE
REITERATEBuy
Sep 24, 2026Wedbush
REITERATE
REITERATEOutperform
Sep 24, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$8.7M
sold · 5 insiders · excl. 6 subscriber-only trades
DateInsiderTypeValue
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
EXERCISE
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
EXERCISE
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL

Earnings setup

Estimates
Nov 18
reports in 2 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
6,464,212
shares short
+5.8%
vs prior settlement
7.1
days to cover
≈9.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Insider
🔒 Fresh data, subscribers only
Nov 16, 2026 Insider
🔒 Fresh data, subscribers only
Nov 16, 2026 Insider
🔒 Fresh data, subscribers only
Nov 13, 2026 SEC
Two insiders at Oruka Therapeutics (ORKA) executed open-market sales totaling $173K on November 12, 2026, both under…
CLUSTER · Impact 2/10
Nov 9, 2026 Earnings
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, high
Oct 25, 2026 Press
Oruka Therapeutics will report Week 16 data for its lead candidate ORKA-001 from the EVERLAST-B Phase 2b trial in…
Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Upcoming
Recent
Nov 9, 2026
Earnings
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A
Nov 3, 2026
Press release
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company…
Oct 25, 2026
FDA
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company…
Oct 15, 2026
Short interest
Short Interest: ORKA down 21% to 6.1M shares
Settlement 2026-10-15 | Days to cover: 7.26 | ≈9.23% of shares outstanding (est.)
Sep 23, 2026
Press release
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4

SecBot reports

36 filings · 4 press releases · 5 bullish · 5 bearish · 26 neutral
All ORKA filing & press-release reports (40)